Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Nonalcoholic fatty liver disease (NAFLD) was first described as a distinct clinical entity four
decades ago. However, the condition has become the centre of attention within hepatology …

Background Inflammatory cytokines have been considered to be significant factors
contributing to the development and progression of non-alcoholic fatty liver disease …

BACKGROUND An increase in intrahepatic triglyceride (IHTG) is the hallmark feature of
nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

Gut microbiota is involved in obesity, metabolic syndrome and the progression of
nonalcoholic fatty liver disease (NAFLD). It has been recently suggested that the flavonoid …

Obesity is regarded to be associated with fat accumulation, chronic inflammation, and gut
microbiota dysbiosis. Raw and ripened pu-erh tea extract (PETe) have the effect of reducing …

Nonalcoholic fatty liver disease (NAFLD) is an increasing global public health burden.
NAFLD is strongly associated with type 2 diabetes mellitus, obesity and cardiovascular …

Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological change characterized by
the accumulation of triglycerides in hepatocytes and has frequently been associated with …

Background & Aims Peroxisome proliferator-activated receptors (PPARs) have been
implicated in non-alcoholic steatohepatitis (NASH) pathogenesis, mainly based on animal …